Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Pfizer Drug Patent Portfolio

Pfizer owns 31 orange book drugs protected by 109 US patents with Arthrotec having the least patent protection, holding only 1 patent. And Toviaz with maximum patent protection, holding 12 patents. Given below is the list of Pfizer's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11541034 Nitrile-containing antiviral compounds 31 Oct, 2041
Active
US12116368 Pyrrolo[2,3-d]pyrimidine tosylate salt, crystalline form thereof and manufacturing process and intermediates thereto 17 Oct, 2041
Active
US11351149 Nitrile-containing antiviral compounds 05 Aug, 2041
Active
US11083724 Rimegepant for CGRP related disorders 25 Mar, 2039
Active
US11299500 Crystalline form of lorlatinib free base hydrate 04 Oct, 2038
Active
US11065250 Solid dosage forms of palbociclib 19 Aug, 2036
Active
US10420749 Crystalline form of lorlatinib free base 27 Jul, 2036
Active
US11020376 Crystalline form of lorlatinib free base 27 Jul, 2036
Active
US10301262 Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders 21 Jun, 2036
Active
US10676435 Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound 1) for use in SIPI receptor-associated disorders 21 Jun, 2036
Active
US11091435 Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3, 4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(compound1) for use in S1P1 receptor-associated disorders 21 Jun, 2036
Active
US11884626 Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound1) for use in S1P1 receptor-associated disorders 21 Jun, 2036
Active
US10414748 Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate 13 Apr, 2036
Active
US11168066 Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate 13 Apr, 2036
Active
US11891372 Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate 13 Apr, 2036
Active
US11007175 Methods of treating conditions related to the S1P1 receptor 06 Jan, 2036
Active
US12077533 Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides 03 Dec, 2034
Active
US9617258 Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides 03 Dec, 2034
Active
US10639309 Tofacitinib oral sustained release dosage forms 14 Mar, 2034
Active
US11253523 Tofacitinib oral sustained release dosage forms 14 Mar, 2034
Active
US9937181 Tofacitinib oral sustained release dosage forms 14 Mar, 2034
Active
US9035074 Pyrrolo[2,3-D]pyrimidine derivatives 19 Feb, 2034
Active
US9545405 Pyrrolo[2,3-D]pyrimidine derivatives 19 Feb, 2034
Active
US9549929 Pyrrolo[2,3-D]pyrimidine derivatives 19 Feb, 2034
Active
US10723730 Solid forms of a selective CDK4/6 inhibitor 08 Feb, 2034
Active
US8680111 Macrocyclic derivatives for the treatment of diseases 05 Mar, 2033
Active
US8759372 N-(5S,6S,9R)-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-ctclohepta[b]Pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-carboxylate salt 25 Feb, 2033
Active
US10189837 Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt 20 Oct, 2031
Active
US8735392 Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt 20 Oct, 2031
Active
US8481546 CGRP receptor antagonist 07 Oct, 2031
Active
US8148401 Benzimidazole derivatives 30 Jan, 2031
Active
US8314117 CGRP receptor antagonists 09 Mar, 2030
Active
US8580841 Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders 05 Mar, 2030
Active
US8012976 Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) 19 Oct, 2029
Active
US10780088 Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) 27 Jul, 2029
Active
US8420650 Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) 27 Jul, 2029
Active
US9820985 Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) 27 Jul, 2029
Active
US9126932 Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders 22 Jul, 2029
Active
US7772243 4-phenylamino-quinazolin-6-yl-amides 26 Aug, 2028
Active
US8431597 Benzimidazole derivatives 29 Jun, 2028
Active
US7815934 Sequestering subunit and related compositions and methods 12 Dec, 2027
Active
US7807715 Pharmaceutical compositions comprising fesoterodine 07 Dec, 2027
Active
US8088398 Pharmaceutical compositions comprising fesoterodine 07 Dec, 2027
Active
US8501723 Pharmaceutical compositions comprising fesoterodine 07 Dec, 2027
Active
US7807715 Pharmaceutical compositions comprising fesoterodine 07 Jun, 2027
Active
US8088398 Pharmaceutical compositions comprising fesoterodine 07 Jun, 2027
Active
US8501723 Pharmaceutical compositions comprising fesoterodine 07 Jun, 2027
Active
USRE47739 2-(pyridin-2-ylamino)-pyrido[2,3-D]pyrimidin-7-ones 05 Mar, 2027
Active
US10596162 Method for treating gefitinib resistant cancer 02 Feb, 2026
Active
US10603314 Method for treating gefitinib resistant cancer 02 Feb, 2026
Active
USRE41783 Pyrrolo[2,3-D]pyrimidine compounds 08 Dec, 2025
Active
US8790641 Production of high mannose proteins in plant culture and therapeutic uses thereof 18 Oct, 2025
Active
US8685443 Sequestering subunit and related compositions and methods 03 Jul, 2025
Active
US8623883 4-phenylamino-quinazolin-6-yl-amides 05 May, 2025
Active
US8227230 Human lysosomal proteins from plant cell culture 24 Feb, 2024 Expired
US8741620 Human lysosomal proteins from plant cell culture 24 Feb, 2024 Expired
US7220862 Calcitonin gene related peptide receptor antagonists 21 Jan, 2024 Expired
US7314883 Anti-migraine treatments 05 Dec, 2023 Expired
US6956027 N-terminally chemically modified protein compositions and methods 25 Mar, 2023 Expired
US6965027 Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate 25 Mar, 2023 Expired
US6936612 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones 16 Jan, 2023 Expired
US7208489 2-(pyridin-2-ylamino)-pyrido [2,3-d]pyrimidin-7-ones 16 Jan, 2023 Expired
US7456168 2-(pyridin-2-ylamino)-pyrido[2,3, d]pyrimidin-7-ones 16 Jan, 2023 Expired
US6858650 Stable salts of novel derivatives of 3,3-diphenylpropylamines 03 Jan, 2023 Expired
US6858650 Stable salts of novel derivatives of 3,3-diphenylpropylamines 03 Jul, 2022 Expired
US6514529 Oxazolidinone tablet formulation 15 Sep, 2021 Expired
US6559305 Linezolid—crystal form II 29 Jul, 2021 Expired
US6514529 Oxazolidinone tablet formulation 15 Mar, 2021 Expired
US6559305 Linezolid—crystal form II 29 Jan, 2021 Expired
US6956041 Pyrrolo[2,3-d]pyrimidine compounds 08 Dec, 2020 Expired
US7091208 Pyrrolo[2,3-D]pyrimidine compounds 08 Dec, 2020 Expired
US7265221 Pyrrolo[2,3-d]pyrimidine compounds 08 Dec, 2020 Expired
US7301023 Chiral salt resolution 08 Dec, 2020 Expired
US7842699 Pyrrolo[2,3-D]pyrimidine compounds 08 Dec, 2020 Expired
US6495157 Intravaginal clindamycin ovule composition 20 Jul, 2020 Expired
US6582728 Spray drying of macromolecules to produce inhaleable dry powders 24 Jun, 2020 Expired
US6495534 Stabilized aqueous suspensions for parenteral use 15 May, 2020 Expired
US6257233 Dry powder dispersing apparatus and methods for their use 14 May, 2019 Expired
US6546929 Dry powder dispersing apparatus and methods for their use 14 May, 2019 Expired
US7384980 Derivatives of 3,3-diphenylpropylamines 11 May, 2019 Expired
US7855230 Derivatives of 3,3-diphenylpropylamines 11 May, 2019 Expired
US7985772 Derivatives of 3,3-diphenylpropylamines 11 May, 2019 Expired
US8338478 Derivatives of 3,3-diphenylpropylamines 11 May, 2019 Expired
USRE44459 Method for lowering blood glucose 26 Mar, 2019 Expired
US6187341 Trovafloxacin mesylate tablet 20 Jan, 2019 Expired
US6124363 Dofetilide polymorphs 09 Oct, 2018 Expired
US6685967 Methods and compositions for pulmonary delivery of insulin 11 Sep, 2018 Expired
US6268489 Azithromycin dihydrate 31 Jul, 2018 Expired
US6194429 Alatrofloxacin parenteral compositions 23 Jul, 2018 Expired
US6103262 Modified-release metronidazole compositions and methods for making and using same 15 Aug, 2017 Expired
US6096339 Dosage form, process of making and using same 04 Apr, 2017 Expired
US6080756 Polymorphs of the prodrug 6-N-(L-ALA-L-ALA)-trovafloxacin 05 Jul, 2016 Expired
US5763454 Crystal form of anhydrous 7-( 1α,5α,6α!-6-amino-3-azabicyclo 3.1.0!hex-3-yl)-6-fluoro-1-(2,4-difluorophenyl)-1,4-dihydro-4-oxo-1,8 naphthyridine-3-carboxylic acid, methanessulfonic acid salt 15 Jun, 2015 Expired
US5688792 Substituted oxazine and thiazine oxazolidinone antimicrobials 18 May, 2015 Expired
US5741523 Stabilized prostaglandin E1 21 Apr, 2015 Expired
US5740794 Apparatus and methods for dispersing dry powder medicaments 21 Apr, 2015 Expired
US5716338 Dual-chamber type injection cartridge with bypass connection 10 Feb, 2015 Expired
US5688792 Substituted oxazine and thiazine oxazolidinone antimicrobials 18 Nov, 2014 Expired
US6543448 Apparatus and methods for dispersing dry powder medicaments 21 Sep, 2014 Expired
US5997848 Methods and compositions for pulmonary delivery of insulin 07 Mar, 2014 Expired
US6051256 Dispersible macromolecule compositions and methods for their preparation and use 07 Mar, 2014 Expired
US6423344 Dispersible macromolecule compositions and methods for their preparation and use 07 Mar, 2014 Expired
US6592904 Dispersible macromolecule compositions and methods for their preparation and use 07 Mar, 2014 Expired
US6737045 Methods and compositions for the pulmonary delivery insulin 07 Mar, 2014 Expired
US5601843 Pharmaceutical tablet composition 11 Feb, 2014 Expired
US5591454 Method for lowering blood glucose 07 Jan, 2014 Expired
US5501673 Injection cartridge 16 Apr, 2013 Expired
US5490987 Tableting of colestipol hydrochloride 13 Feb, 2013 Expired
US4959366 Anti-arrhythmic agents 25 Sep, 2012 Expired


Given below is the list of recent legal activities going on the following drug patents of Pfizer.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 13 Jun, 2024 US9545405
Payment of Maintenance Fee, 8th Year, Large Entity 13 Jun, 2024 US9549929
Second letter to regulating agency to determine regulatory review period 16 May, 2024 US8580841
Letter from FDA or Dept of Agriculture re PTE application 08 May, 2024 US8580841
Payment of Maintenance Fee, 12th Year, Large Entity 11 Apr, 2024 US8314117
Information Disclosure Statement (IDS) Filed
Critical
04 Apr, 2024 US11351149
transaction for FDA Determination of Regulatory Review Period 14 Mar, 2024 US9545405
transaction for FDA Determination of Regulatory Review Period 14 Mar, 2024 US9035074
transaction for FDA Determination of Regulatory Review Period 13 Mar, 2024 US8431597
transaction for FDA Determination of Regulatory Review Period 13 Mar, 2024 US8148401
Maintenance Fee Reminder Mailed
Critical
11 Mar, 2024 US8227230
transaction for FDA Determination of Regulatory Review Period 29 Feb, 2024 US9035074
transaction for FDA Determination of Regulatory Review Period 29 Feb, 2024 US9545405
transaction for FDA Determination of Regulatory Review Period 28 Feb, 2024 US8431597
Post Issue Communication - Certificate of Correction 28 Feb, 2024 US11891372


Pfizer's Drug Patent Litigations

Pfizer's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jan 01, 1, against patent number US6268489. The petitioner , challenged the validity of this patent, with ALLEN et al as the respondent. Click below to track the latest information on how companies are challenging Pfizer's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US6858650 January, 2016 FWD Entered
(19 Jul, 2017)
UCB Pharma GmbH Mylan Pharmaceuticals Inc
US6858650 August, 2016 FWD Entered
(19 Jul, 2017)
UCB Pharma GmbH Torrent Pharmaceuticals Limited
US6858650 August, 2016 FWD Entered
(19 Jul, 2017)
UCB Pharma GmbH Alembic Pharmaceuticals Limited
US6858650 August, 2016 FWD Entered
(19 Jul, 2017)
UCB Pharma GmbH Amerigen Pharmaceuticals Limited
US7384980 January, 2016 FWD Entered
(19 Jul, 2017)
UCB Pharma GmbH Mylan Pharmaceuticals Inc.
US7855230 January, 2016 FWD Entered
(19 Jul, 2017)
UCB Pharma GmbH Mylan Pharmaceuticals Inc.
US7985772 January, 2016 FWD Entered
(19 Jul, 2017)
UCB Pharma GmbH Mylan Pharmaceuticals Inc.
US8338478 January, 2016 FWD Entered
(19 Jul, 2017)
UCB Pharma GmbH Mylan Pharmaceuticals Inc.
US6685967 April, 2002 Decision
(23 Jan, 2003)
PATTON et al
US6268489 January, 1 Decision
(15 Apr, 1998)
ALLEN et al


Pfizer Drug Patents' Oppositions Filed in EPO

Pfizer drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Nov 09, 2011, by Wibbelmann, Jobst. This opposition was filed on patent number EP02781589A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP18186675A Jan, 2022 Generics [UK] Limited Granted and Under Opposition
EP18186675A Jan, 2022 Galenicum Health S.L.U. Granted and Under Opposition
EP18186675A Jan, 2022 Teva Pharmaceutical Industries Ltd. Granted and Under Opposition
EP18186675A Jan, 2022 STADA Arzneimittel AG Granted and Under Opposition
EP14726410A Dec, 2021 Teva Pharmaceutical Industries Ltd. Granted and Under Opposition
EP14726410A Dec, 2021 Lederer & Keller Patentanwälte Partnerschaft mbB Granted and Under Opposition
EP14726410A Dec, 2021 STADA Arzneimittel AG Granted and Under Opposition
EP14726410A Dec, 2021 Generics (U.K.) Limited Granted and Under Opposition
EP14726410A Dec, 2021 Greiner, Elisabeth Granted and Under Opposition
EP14726410A Nov, 2021 Aera A/S Granted and Under Opposition
EP16726192A Aug, 2020 Generics [UK] Limited Granted and Under Opposition
EP16726192A Aug, 2020 Synthon BV Granted and Under Opposition
EP16726192A Aug, 2020 Hexal AG Granted and Under Opposition
EP16726192A Aug, 2020 Galenicum Health S.L. Granted and Under Opposition
EP16726192A Aug, 2020 Hoffmann Eitle Granted and Under Opposition
EP16726192A Aug, 2020 Teva Pharmaceutical Industries Ltd Granted and Under Opposition
EP14705884A Jun, 2019 Galenicum Health S.L.U. Granted and Under Opposition
EP14705884A Jun, 2019 Teva Pharmaceutical Industries Ltd Granted and Under Opposition
EP14705884A Jun, 2019 Generics (UK) Ltd Granted and Under Opposition
EP06720163A Nov, 2011 BOEHRINGER INGELHEIM INTERNATIONAL GMBH Granted and Under Opposition
EP02781589A Nov, 2011 Wibbelmann, Jobst Opposition rejected


Pfizer's Family Patents

Pfizer drugs have patent protection in a total of 64 countries. It's US patent count contributes only to 13.8% of its total global patent coverage. 10 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Pfizer Drug List

Given below is the complete list of Pfizer's drugs and the patents protecting them.


1. Arthrotec

Arthrotec is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5601843 Pharmaceutical tablet composition 11 Feb, 2014
(10 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Arthrotec's drug page


2. Caverject

Caverject is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5741523 Stabilized prostaglandin E1 21 Apr, 2015
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Caverject's drug page


3. Caverject Impulse

Caverject Impulse is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5716338 Dual-chamber type injection cartridge with bypass connection 10 Feb, 2015
(9 years ago)
Expired
US5501673 Injection cartridge 16 Apr, 2013
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Caverject Impulse's drug page


4. Cibinqo

Cibinqo is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9035074 Pyrrolo[2,3-D]pyrimidine derivatives 19 Feb, 2034
(9 years from now)
Active
US9545405 Pyrrolo[2,3-D]pyrimidine derivatives 19 Feb, 2034
(9 years from now)
Active
US9549929 Pyrrolo[2,3-D]pyrimidine derivatives 19 Feb, 2034
(9 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cibinqo's drug page


5. Cleocin

Cleocin is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6495157 Intravaginal clindamycin ovule composition 20 Jul, 2020
(4 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cleocin's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

6. Colestid

Colestid is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5490987 Tableting of colestipol hydrochloride 13 Feb, 2013
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Colestid's drug page


7. Covera-hs

Covera-hs is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6096339 Dosage form, process of making and using same 04 Apr, 2017
(7 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Covera-hs's drug page


8. Daurismo

Daurismo is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10414748 Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate 13 Apr, 2036
(11 years from now)
Active
US11168066 Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate 13 Apr, 2036
(11 years from now)
Active
US11891372 Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate 13 Apr, 2036
(11 years from now)
Active
US8148401 Benzimidazole derivatives 30 Jan, 2031
(6 years from now)
Active
US8431597 Benzimidazole derivatives 29 Jun, 2028
(3 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Daurismo's drug page


9. Depo-subq Provera 104

Depo-subq Provera 104 is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6495534 Stabilized aqueous suspensions for parenteral use 15 May, 2020
(4 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Depo-subq Provera 104's drug page


10. Elelyso

Elelyso is protected by 3 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8790641 Production of high mannose proteins in plant culture and therapeutic uses thereof 18 Oct, 2025
(10 months from now)
Active
US8227230 Human lysosomal proteins from plant cell culture 24 Feb, 2024
(8 months ago)
Expired
US8741620 Human lysosomal proteins from plant cell culture 24 Feb, 2024
(8 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Elelyso's drug page


11. Exubera

Exubera is protected by 11 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6582728 Spray drying of macromolecules to produce inhaleable dry powders 24 Jun, 2020
(4 years ago)
Expired
US6257233 Dry powder dispersing apparatus and methods for their use 14 May, 2019
(5 years ago)
Expired
US6546929 Dry powder dispersing apparatus and methods for their use 14 May, 2019
(5 years ago)
Expired
US6685967 Methods and compositions for pulmonary delivery of insulin 11 Sep, 2018
(6 years ago)
Expired
US5740794 Apparatus and methods for dispersing dry powder medicaments 21 Apr, 2015
(9 years ago)
Expired
US6543448 Apparatus and methods for dispersing dry powder medicaments 21 Sep, 2014
(10 years ago)
Expired
US5997848 Methods and compositions for pulmonary delivery of insulin 07 Mar, 2014
(10 years ago)
Expired
US6051256 Dispersible macromolecule compositions and methods for their preparation and use 07 Mar, 2014
(10 years ago)
Expired
US6423344 Dispersible macromolecule compositions and methods for their preparation and use 07 Mar, 2014
(10 years ago)
Expired
US6592904 Dispersible macromolecule compositions and methods for their preparation and use 07 Mar, 2014
(10 years ago)
Expired
US6737045 Methods and compositions for the pulmonary delivery insulin 07 Mar, 2014
(10 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Exubera's drug page


12. Flagyl Er

Flagyl Er is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6103262 Modified-release metronidazole compositions and methods for making and using same 15 Aug, 2017
(7 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Flagyl Er's drug page


13. Glucotrol Xl

Glucotrol Xl is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
USRE44459 Method for lowering blood glucose 26 Mar, 2019
(5 years ago)
Expired
US5591454 Method for lowering blood glucose 07 Jan, 2014
(10 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Glucotrol Xl's drug page


14. Ibrance

Ibrance is protected by 6 patents, out of which 3 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11065250 Solid dosage forms of palbociclib 19 Aug, 2036
(11 years from now)
Active
US10723730 Solid forms of a selective CDK4/6 inhibitor 08 Feb, 2034
(9 years from now)
Active
USRE47739 2-(pyridin-2-ylamino)-pyrido[2,3-D]pyrimidin-7-ones 05 Mar, 2027
(2 years from now)
Active
US6936612 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones 16 Jan, 2023
(1 year, 10 months ago)
Expired
US7208489 2-(pyridin-2-ylamino)-pyrido [2,3-d]pyrimidin-7-ones 16 Jan, 2023
(1 year, 10 months ago)
Expired
US7456168 2-(pyridin-2-ylamino)-pyrido[2,3, d]pyrimidin-7-ones 16 Jan, 2023
(1 year, 10 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ibrance's drug page


15. Litfulo

Litfulo is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12116368 Pyrrolo[2,3-d]pyrimidine tosylate salt, crystalline form thereof and manufacturing process and intermediates thereto 17 Oct, 2041
(16 years from now)
Active
US12077533 Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides 03 Dec, 2034
(10 years from now)
Active
US9617258 Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides 03 Dec, 2034
(10 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Litfulo's drug page


16. Lorbrena

Lorbrena is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11299500 Crystalline form of lorlatinib free base hydrate 04 Oct, 2038
(13 years from now)
Active
US10420749 Crystalline form of lorlatinib free base 27 Jul, 2036
(11 years from now)
Active
US11020376 Crystalline form of lorlatinib free base 27 Jul, 2036
(11 years from now)
Active
US8680111 Macrocyclic derivatives for the treatment of diseases 05 Mar, 2033
(8 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lorbrena's drug page


17. Nurtec Odt

Nurtec Odt is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11083724 Rimegepant for CGRP related disorders 25 Mar, 2039
(14 years from now)
Active
US8759372 N-(5S,6S,9R)-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-ctclohepta[b]Pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-carboxylate salt 25 Feb, 2033
(8 years from now)
Active
US8314117 CGRP receptor antagonists 09 Mar, 2030
(5 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nurtec Odt's drug page


18. Paxlovid (copackaged)

Paxlovid (copackaged) is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11541034 Nitrile-containing antiviral compounds 31 Oct, 2041
(16 years from now)
Active
US11351149 Nitrile-containing antiviral compounds 05 Aug, 2041
(16 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Paxlovid (copackaged)'s drug page


19. Talzenna

Talzenna is protected by 6 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10189837 Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt 20 Oct, 2031
(6 years from now)
Active
US8735392 Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt 20 Oct, 2031
(6 years from now)
Active
US8012976 Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) 19 Oct, 2029
(4 years from now)
Active
US10780088 Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) 27 Jul, 2029
(4 years from now)
Active
US8420650 Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) 27 Jul, 2029
(4 years from now)
Active
US9820985 Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) 27 Jul, 2029
(4 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Talzenna's drug page


20. Tikosyn

Tikosyn is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6124363 Dofetilide polymorphs 09 Oct, 2018
(6 years ago)
Expired
US4959366 Anti-arrhythmic agents 25 Sep, 2012
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tikosyn's drug page


21. Toviaz

Toviaz is protected by 12 patents, out of which 6 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7807715
(Pediatric)
Pharmaceutical compositions comprising fesoterodine 07 Dec, 2027
(3 years from now)
Active
US8088398
(Pediatric)
Pharmaceutical compositions comprising fesoterodine 07 Dec, 2027
(3 years from now)
Active
US8501723
(Pediatric)
Pharmaceutical compositions comprising fesoterodine 07 Dec, 2027
(3 years from now)
Active
US7807715 Pharmaceutical compositions comprising fesoterodine 07 Jun, 2027
(2 years from now)
Active
US8088398 Pharmaceutical compositions comprising fesoterodine 07 Jun, 2027
(2 years from now)
Active
US8501723 Pharmaceutical compositions comprising fesoterodine 07 Jun, 2027
(2 years from now)
Active
US6858650
(Pediatric)
Stable salts of novel derivatives of 3,3-diphenylpropylamines 03 Jan, 2023
(1 year, 10 months ago)
Expired
US6858650 Stable salts of novel derivatives of 3,3-diphenylpropylamines 03 Jul, 2022
(2 years ago)
Expired
US7384980 Derivatives of 3,3-diphenylpropylamines 11 May, 2019
(5 years ago)
Expired
US7855230 Derivatives of 3,3-diphenylpropylamines 11 May, 2019
(5 years ago)
Expired
US7985772 Derivatives of 3,3-diphenylpropylamines 11 May, 2019
(5 years ago)
Expired
US8338478 Derivatives of 3,3-diphenylpropylamines 11 May, 2019
(5 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Toviaz's drug page


22. Trovan

Trovan is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6187341 Trovafloxacin mesylate tablet 20 Jan, 2019
(5 years ago)
Expired
US5763454 Crystal form of anhydrous 7-( 1α,5α,6α!-6-amino-3-azabicyclo 3.1.0!hex-3-yl)-6-fluoro-1-(2,4-difluorophenyl)-1,4-dihydro-4-oxo-1,8 naphthyridine-3-carboxylic acid, methanessulfonic acid salt 15 Jun, 2015
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Trovan's drug page


23. Trovan Preservative Free

Trovan Preservative Free is protected by 3 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6194429 Alatrofloxacin parenteral compositions 23 Jul, 2018
(6 years ago)
Expired
US6080756 Polymorphs of the prodrug 6-N-(L-ALA-L-ALA)-trovafloxacin 05 Jul, 2016
(8 years ago)
Expired
US5763454 Crystal form of anhydrous 7-( 1α,5α,6α!-6-amino-3-azabicyclo 3.1.0!hex-3-yl)-6-fluoro-1-(2,4-difluorophenyl)-1,4-dihydro-4-oxo-1,8 naphthyridine-3-carboxylic acid, methanessulfonic acid salt 15 Jun, 2015
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Trovan Preservative Free's drug page


24. Troxyca Er

Troxyca Er is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7815934 Sequestering subunit and related compositions and methods 12 Dec, 2027
(3 years from now)
Active
US8685443 Sequestering subunit and related compositions and methods 03 Jul, 2025
(7 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Troxyca Er's drug page


25. Velsipity

Velsipity is protected by 7 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10301262 Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders 21 Jun, 2036
(11 years from now)
Active
US10676435 Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound 1) for use in SIPI receptor-associated disorders 21 Jun, 2036
(11 years from now)
Active
US11091435 Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3, 4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(compound1) for use in S1P1 receptor-associated disorders 21 Jun, 2036
(11 years from now)
Active
US11884626 Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound1) for use in S1P1 receptor-associated disorders 21 Jun, 2036
(11 years from now)
Active
US11007175 Methods of treating conditions related to the S1P1 receptor 06 Jan, 2036
(11 years from now)
Active
US8580841 Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders 05 Mar, 2030
(5 years from now)
Active
US9126932 Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders 22 Jul, 2029
(4 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Velsipity's drug page


26. Vizimpro

Vizimpro is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7772243 4-phenylamino-quinazolin-6-yl-amides 26 Aug, 2028
(3 years from now)
Active
US10596162 Method for treating gefitinib resistant cancer 02 Feb, 2026
(1 year, 2 months from now)
Active
US10603314 Method for treating gefitinib resistant cancer 02 Feb, 2026
(1 year, 2 months from now)
Active
US8623883 4-phenylamino-quinazolin-6-yl-amides 05 May, 2025
(5 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vizimpro's drug page


27. Xeljanz

Xeljanz is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
USRE41783 Pyrrolo[2,3-D]pyrimidine compounds 08 Dec, 2025
(1 year, 16 days from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xeljanz's drug page


28. Xeljanz Xr

Xeljanz Xr is protected by 11 patents, out of which 7 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10639309 Tofacitinib oral sustained release dosage forms 14 Mar, 2034
(9 years from now)
Active
US11253523 Tofacitinib oral sustained release dosage forms 14 Mar, 2034
(9 years from now)
Active
US9937181 Tofacitinib oral sustained release dosage forms 14 Mar, 2034
(9 years from now)
Active
USRE41783 Pyrrolo[2,3-D]pyrimidine compounds 08 Dec, 2025
(1 year, 16 days from now)
Active
US6956027 N-terminally chemically modified protein compositions and methods 25 Mar, 2023
(1 year, 7 months ago)
Expired
US6965027 Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate 25 Mar, 2023
(1 year, 7 months ago)
Expired
US6956041 Pyrrolo[2,3-d]pyrimidine compounds 08 Dec, 2020
(3 years ago)
Expired
US7091208 Pyrrolo[2,3-D]pyrimidine compounds 08 Dec, 2020
(3 years ago)
Expired
US7265221 Pyrrolo[2,3-d]pyrimidine compounds 08 Dec, 2020
(3 years ago)
Expired
US7301023 Chiral salt resolution 08 Dec, 2020
(3 years ago)
Expired
US7842699 Pyrrolo[2,3-D]pyrimidine compounds 08 Dec, 2020
(3 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xeljanz Xr's drug page


29. Zavzpret

Zavzpret is protected by 3 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8481546 CGRP receptor antagonist 07 Oct, 2031
(6 years from now)
Active
US7220862 Calcitonin gene related peptide receptor antagonists 21 Jan, 2024
(10 months ago)
Expired
US7314883 Anti-migraine treatments 05 Dec, 2023
(11 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zavzpret's drug page


30. Zithromax

Zithromax is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6268489 Azithromycin dihydrate 31 Jul, 2018
(6 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zithromax's drug page


31. Zyvox

Zyvox is protected by 6 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6514529
(Pediatric)
Oxazolidinone tablet formulation 15 Sep, 2021
(3 years ago)
Expired
US6559305
(Pediatric)
Linezolid—crystal form II 29 Jul, 2021
(3 years ago)
Expired
US6514529 Oxazolidinone tablet formulation 15 Mar, 2021
(3 years ago)
Expired
US6559305 Linezolid—crystal form II 29 Jan, 2021
(3 years ago)
Expired
US5688792
(Pediatric)
Substituted oxazine and thiazine oxazolidinone antimicrobials 18 May, 2015
(9 years ago)
Expired
US5688792 Substituted oxazine and thiazine oxazolidinone antimicrobials 18 Nov, 2014
(10 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zyvox's drug page


Pfizer News

Essa discontinues development of primary cancer drug following unsuccessful trial compared to Xtandi - Fierce Biotech

01 Nov, 2024

Manufacturer of Zantac agrees to a settlement of $2.2 billion

24 Oct, 2024

Information on Ozempic and Wegovy, prescription medications for weight loss: A comprehensive guide - Quartz

09 Oct, 2024

FDA is set to review the approval of the first new drug for schizophrenia in more than three decades

26 Sep, 2024

See More